MX2011008456A - Anticuerpos anti-mst1r y usos de los mismos. - Google Patents

Anticuerpos anti-mst1r y usos de los mismos.

Info

Publication number
MX2011008456A
MX2011008456A MX2011008456A MX2011008456A MX2011008456A MX 2011008456 A MX2011008456 A MX 2011008456A MX 2011008456 A MX2011008456 A MX 2011008456A MX 2011008456 A MX2011008456 A MX 2011008456A MX 2011008456 A MX2011008456 A MX 2011008456A
Authority
MX
Mexico
Prior art keywords
antibodies
mst1r
disorders
conditions
disclosure
Prior art date
Application number
MX2011008456A
Other languages
English (en)
Spanish (es)
Inventor
Reimi Kawaida
Toshiaki Ohtsuka
Toshinori Agatsuma
Philip Rodley
Sandra Miller
Ulrike Schubert
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MX2011008456A publication Critical patent/MX2011008456A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2011008456A 2009-02-10 2010-02-10 Anticuerpos anti-mst1r y usos de los mismos. MX2011008456A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15141109P 2009-02-10 2009-02-10
PCT/JP2010/052479 WO2010093055A1 (en) 2009-02-10 2010-02-10 Anti-mst1r antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2011008456A true MX2011008456A (es) 2011-09-26

Family

ID=42227811

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008456A MX2011008456A (es) 2009-02-10 2010-02-10 Anticuerpos anti-mst1r y usos de los mismos.

Country Status (18)

Country Link
US (1) US9403909B2 (https=)
EP (1) EP2396084B1 (https=)
JP (1) JP5714511B2 (https=)
KR (1) KR101745025B1 (https=)
CN (1) CN102438702B (https=)
AU (1) AU2010214301B2 (https=)
BR (1) BRPI1007979A2 (https=)
CA (1) CA2752136C (https=)
CO (1) CO6420322A2 (https=)
ES (1) ES2583281T3 (https=)
IL (1) IL214527A0 (https=)
MX (1) MX2011008456A (https=)
NZ (1) NZ594452A (https=)
RU (1) RU2534890C2 (https=)
SG (2) SG2014009195A (https=)
TW (1) TWI480050B (https=)
WO (1) WO2010093055A1 (https=)
ZA (1) ZA201105725B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356749B (es) * 2012-04-27 2018-06-12 Daiichi Sankyo Co Ltd Anticuerpo anti-homologo 4 de roundabout (robo4).
TWI909341B (zh) 2015-09-24 2025-12-21 日商第一三共股份有限公司 抗garp抗體及其製造方法及用途
EP3504244A4 (en) 2016-08-26 2020-08-19 Agency for Science, Technology and Research MACROPHAGE-STIMULATING PROTEIN RECEPTOR ANTIBODIES (OR OF NANTAIS ORIGINAL RON-RECEPTOR) AND THEIR USES
MX2022001812A (es) 2019-08-12 2022-03-11 Regeneron Pharma Variantes del receptor estimulante de macrofagos 1 (mst1r) y sus usos.
WO2021066751A1 (en) * 2019-10-02 2021-04-08 Aslan Pharmaceuticals Pte. Ltd. Antigen specific binding domains and antibody molecules
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
CA2566647A1 (en) * 2004-05-13 2005-12-22 Imclone Systems Incorporated Inhibition of macrophage-stimulating protein receptor (ron)
US20060073256A1 (en) * 2004-06-15 2006-04-06 Frederic Destaillats Self-foaming liquid creamers and processes
JP2008512352A (ja) * 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
UY31478A1 (es) * 2007-11-21 2009-07-17 Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
MX2010008025A (es) * 2008-01-22 2010-08-04 Biogen Idec Inc Anticuerpos ron y usos de los mismos.

Also Published As

Publication number Publication date
EP2396084B1 (en) 2016-05-11
AU2010214301A1 (en) 2011-09-01
US9403909B2 (en) 2016-08-02
KR20110117677A (ko) 2011-10-27
WO2010093055A1 (en) 2010-08-19
TW201036635A (en) 2010-10-16
SG173196A1 (en) 2011-08-29
IL214527A0 (en) 2011-09-27
KR101745025B1 (ko) 2017-06-20
US20120034215A1 (en) 2012-02-09
HK1164193A1 (zh) 2012-09-21
CO6420322A2 (es) 2012-04-16
RU2534890C2 (ru) 2014-12-10
RU2011137405A (ru) 2013-03-20
TWI480050B (zh) 2015-04-11
JP5714511B2 (ja) 2015-05-07
EP2396084A1 (en) 2011-12-21
ZA201105725B (en) 2012-04-25
AU2010214301B2 (en) 2016-11-10
SG2014009195A (en) 2014-04-28
BRPI1007979A2 (pt) 2017-10-03
ES2583281T3 (es) 2016-09-20
CN102438702A (zh) 2012-05-02
JP2012517223A (ja) 2012-08-02
CA2752136A1 (en) 2010-08-19
CN102438702B (zh) 2016-03-02
CA2752136C (en) 2016-03-15
NZ594452A (en) 2013-01-25

Similar Documents

Publication Publication Date Title
IN2012DN05175A (https=)
MY157164A (en) Anti-mesothelin antibodies and uses thereof
MX2015016814A (es) Anticuerpo anti-tweakr y sus usos.
MX2020012327A (es) Anticuerpo antagonista de cd73.
TW200716674A (en) Anti-GM-CSF antibodies and uses therefor
NZ754051A (en) Novel antibodies and uses thereof
WO2005103083A8 (en) Anti-cd38 human antibodies and uses therefor
EP4537906A3 (en) Compositions and methods for delivery of biomacromolecule agents
EA201891366A1 (ru) Гуманизированные антитела против cd73
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
PH12015501284A1 (en) Bcma antigen binding proteins
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
PH12012501337A1 (en) Substituted pyrrolo-aminopyrimidine compounds
MX373485B (es) Miembros de unión al factor de necrosis tumoral (tnf) alfa.
EA201492101A1 (ru) Антитела против fcrn
MX2015005874A (es) Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
PH12015501687A1 (en) Novel binding proteins from pcsk9
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
WO2014151982A3 (en) Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment
MX2011008456A (es) Anticuerpos anti-mst1r y usos de los mismos.
MX2019003077A (es) Anticuerpos novedosos contra el factor xi y sus usos.
PH12012501556A1 (en) Substituted naphthalenyl-pyrimidine compounds
WO2013087929A3 (de) Verfahren zur identifizierung von markersequenzen für gynäkologisches malignom
MX376061B (es) Anticuerpos contra antìgeno de plaqueta 1a humano (hpa-1a).
WO2009130296A3 (en) Anti-alk1 antibodies and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration